ES3005857T3 - Novel peptoids and use thereof for preventing or treating chronic pain - Google Patents

Novel peptoids and use thereof for preventing or treating chronic pain Download PDF

Info

Publication number
ES3005857T3
ES3005857T3 ES21798748T ES21798748T ES3005857T3 ES 3005857 T3 ES3005857 T3 ES 3005857T3 ES 21798748 T ES21798748 T ES 21798748T ES 21798748 T ES21798748 T ES 21798748T ES 3005857 T3 ES3005857 T3 ES 3005857T3
Authority
ES
Spain
Prior art keywords
peptoids
peptoid
trip8b
mice
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21798748T
Other languages
English (en)
Spanish (es)
Inventor
Jérôme Busserolles
Emmanuel Bourinet
Claude Taillefumier
Olivier Roy
Lionel Nauton
Youssef Aissouni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, University of Montpellier, Université Clermont Auvergne, Sigma Clermont filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of ES3005857T3 publication Critical patent/ES3005857T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES21798748T 2020-10-06 2021-09-30 Novel peptoids and use thereof for preventing or treating chronic pain Active ES3005857T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2010186A FR3114739B1 (fr) 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
PCT/FR2021/051694 WO2022074313A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Publications (1)

Publication Number Publication Date
ES3005857T3 true ES3005857T3 (en) 2025-03-17

Family

ID=74553909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21798748T Active ES3005857T3 (en) 2020-10-06 2021-09-30 Novel peptoids and use thereof for preventing or treating chronic pain

Country Status (8)

Country Link
US (1) US20230374067A1 (enExample)
EP (1) EP4225295B1 (enExample)
JP (1) JP7853288B2 (enExample)
CN (1) CN116744957A (enExample)
CA (1) CA3194875A1 (enExample)
ES (1) ES3005857T3 (enExample)
FR (1) FR3114739B1 (enExample)
WO (1) WO2022074313A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
KR20080038408A (ko) * 2005-08-18 2008-05-06 쉬바르츠파르마에이지 근육통 치료를 위한 펩티드 화합물의 신규한 용도
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP7120927B2 (ja) * 2016-06-07 2022-08-17 江蘇恒瑞医薬股▲ふん▼有限公司 フェニルプロパンアミド誘導体ならびにそれらの製造方法および医薬用途
US11753432B2 (en) * 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain

Also Published As

Publication number Publication date
US20230374067A1 (en) 2023-11-23
EP4225295B1 (fr) 2024-11-13
JP7853288B2 (ja) 2026-04-28
EP4225295C0 (fr) 2024-11-13
CA3194875A1 (fr) 2022-04-14
CN116744957A (zh) 2023-09-12
EP4225295A1 (fr) 2023-08-16
WO2022074313A1 (fr) 2022-04-14
JP2023544842A (ja) 2023-10-25
FR3114739B1 (fr) 2022-08-26
FR3114739A1 (fr) 2022-04-08

Similar Documents

Publication Publication Date Title
KR102046830B1 (ko) 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
US12329799B2 (en) Peptidyl inhibitors of calcineurin-NFAT interaction
US12115224B2 (en) Polypeptide conjugates for intracellular delivery of stapled peptides
US20050090449A1 (en) Novel statine derivatives for the treatment of Alzheimer's disease
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
ES2353666T3 (es) Moduladores de uniones comunicantes de péptidos.
US20230174582A1 (en) Vipr2 antagonist peptide
AU2017238246B2 (en) Conjugates of tacrolimus, their compositions, and their uses
JP7853288B2 (ja) 新規ペプトイド及び慢性疼痛の予防又は治療におけるそれらの使用
US20090221513A1 (en) Treatment of Neurodegenerative Disorders
WO2007012838A2 (en) Drug delivery system
CN105440104A (zh) 多肽及相关化合物的透皮给药系统